Provided by Tiger Fintech (Singapore) Pte. Ltd.

UNITED LAB

12.680
-0.120-0.94%
Volume:6.99M
Turnover:89.07M
Market Cap:23.04B
PE:8.15
High:12.980
Open:12.800
Low:12.600
Close:12.800
Loading ...

United Laboratories Unit's Infection Drug Passes Chinese Regulator's Consistency Evaluation

MT Newswires Live
·
15 Apr

United Laboratories International Says Group's Product Cefotaxime Sodium For Injection Passed Consistency Evaluation

Reuters
·
15 Apr

United Laboratories International - Group's Product Cefotaxime Sodium for Injection Passed Consistency Evaluation From Nmpa

THOMSON REUTERS
·
15 Apr

United Laboratories to Repurchase HK$200 Million of Shares; Shares Plunge 18%

MT Newswires Live
·
07 Apr

United Laboratories International - to Buy Back Shares With up to HK$200 Mln in Open Market

THOMSON REUTERS
·
07 Apr

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

Reuters
·
28 Mar

Zhongtai International Downgrades The United Laboratories International to Neutral from Buy; Price Target is HK$14.50

MT Newswires Live
·
28 Mar

United Laboratories International Says Final Dividend Of RMB28 Cents Per Share

Reuters
·
25 Mar

United Laboratories International - Final Dividend of RMB28 Cents per Share

THOMSON REUTERS
·
25 Mar

The United Laboratories International Posts 1.5% Decline in 2024 Profit

MT Newswires Live
·
25 Mar

Stock Track | United Laboratories Plummets 5.53% Despite $2 Billion Deal with Novo Nordisk, Dividend Announcements

Stock Track
·
25 Mar

What The United Laboratories International Holdings Limited's (HKG:3933) 26% Share Price Gain Is Not Telling You

Simply Wall St.
·
25 Mar

BRIEF-United Laboratories International Declares Special Dividend

Reuters
·
24 Mar

United Laboratories International Holdings FY Net Income RMB 2,659.7 Million

THOMSON REUTERS
·
24 Mar

BRIEF-United Laboratories International Announces Exclusive License Agreement With Novo Nordisk

Reuters
·
24 Mar

BRIEF-United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Reuters
·
24 Mar

Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug -- Update

Dow Jones
·
24 Mar

the United Laboratories and Novo Nordisk Announce Exclusive License Agreement for Ubt251, a Glp-1/Gip/Glucagon Triple Receptor Agonist

THOMSON REUTERS
·
24 Mar

Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug

Dow Jones
·
24 Mar

Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech

Reuters
·
24 Mar